Official Title
Evaluation of the Performance of COVIDISC Rapid Test for Diagnosis of SARS-CoV-2
Brief Summary

The Covid-19 pandemic requires a reliable diagnosis of patients in order to take care of them in the best conditions and in the appropriate services. Moreover, the current diagnostic reference is reverse transcription by polymerase chain reaction (RT-PCR) on a nasopharyngeal sample taken by swab. This technique is expensive (54€) and its production time is several hours. Alternative methods are in progress, including, rapid diagnostic tests. The MEMS microfluids and nanostructures (MMN) laboratory, in partnership with the Institut Chimie Biologie Innovation (CBI) (Paris, 75005), have developed a portable test "COVIDISC", low-cost (10 €), fast (1 hour), including extraction, elution and amplification in solid medium isothermal, reverse amplification loop mediated transcription (RT-LAMP). The "lab" version has received an analytical validation on human nasopharyngeal samples with performance comparable to classic RT-PCR (sensitivity of 7 copies per μl, specificity 100%). The objective of this study is to validate the in vitro diagnostic medical device, COVIDISC, with the standard nasopharyngeal RT-PCR test.

Detailed Description

All outpatients and hospitalized patients (intensive care unit, internal medicine service and
emergency service) will be proposed to participate to the study after assessment of
eligibility criteria by the investigator. The investigator will collect a written consent of
the patient or from the support person or a familiar if, the patient is not in condition to
consent. Patient's participation will be notified in his medical record.

After inclusion of patient, the nurse will collect general and clinical data and 2
nasopharyngeal swabs will be taken. One sample to test the prototype of the RT-LAMP and the
second one to carry out the classic RT-PCR. The results will be collected and compared in a
second step.

Terminated
COVID-19
SARS-CoV-2

Diagnostic Test: Rapid Diagnostic Test vs PCR

2 nasopharyngeal swabs taken for PCR and COVIDISC

Eligibility Criteria

Inclusion Criteria:

- Patients undergoing nasopharyngeal SARS CoV2 RT-PCR testing

Exclusion Criteria:

- < 18 years old

- Having signed a written informed consent form,

- Affiliation to the social security system.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

CHI Robert Ballanger
Aulnay-sous-Bois, France

CMC Ambroise Paré
NCT Number
MeSH Terms
COVID-19